J Korean Diabetes > Volume 16(4); 2015 > Article
The Journal of Korean Diabetes 2015;16(4):303-309.
DOI: https://doi.org/10.4093/jkd.2015.16.4.303    Published online December 24, 2015.
제2형 당뇨병 환자에서 Vildagliptin이 Visfatin에 미치는 효과: 전향적 연구
장영환, 인동현, 양재국, 문혁진, 윤규태, 류아정, 김여주, 이은영, 김현진, 구본정, 이재민
The Effect of Vildagliptin on Visfatin in Korean Patients with Type 2 Diabetes: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Prospective Study.
Young Hwan Jang, Dong Hyun In, Jae Kook Yang, Hyuk Jin Moon, Gyu Tae Yoon, Ah Jeong Ryu, Yeo Joo Kim, Eun Young Lee, Hyun Jin Kim, Bon Jeong Ku, Jae Min Lee, Kang Seo Park, In Suk Lee, Jong Min Lee, Dong Mee Lim, Keun Yong Park, Sang Jin Kim
1Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea. ksj1113@schmc.ac.kr
2Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
3Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea.
4Department of Internal Medicine, The Catholic University Daejeon St. Mary's Hospital, Daejeon, Korea.
5Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
The effects of dipeptidyl peptidase-4 inhibitors on adipokines remain obscure. The aim of this study was to evaluate the effect of the addition of vildagliptin on visfatin, an adipokine that represents inflammatory biomarkers of adipose tissue, in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy. METHODS: In this 16-week, double-blind, randomized, parallel-group, placebo-controlled study, 71 patients were randomly assigned to vildagliptin 50 mg twice a day (n = 35) or placebo (n = 36) added to ongoing metformin therapy. Fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), plasma lipids, and visfatin levels were measured at baseline and 16 weeks after treatment. RESULTS: After 16 weeks, significant reduction in HbA1c and FPG was observed with vildagliptin addon treatment compared to placebo (-0.54 +/- 0.52%, P = 0.001 and -14.80 +/- 19.21 mg/dL, P = 0.004, respectively). However, no other clinically meaningful changes in lipid parameters or visfatin were observed. CONCLUSION: Vildagliptin add-on to metformin significantly improved fasting blood glucose and HbA1c. However, in this study, no significant differences in lipid parameters or visfatin level were observed between the two groups.
Key Words: Diabetes mellitus, Type 2, Vildagliptin, Visfatin

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer